Getting a Definitive Diagnosis for PARK19A
At a Glance
PARK19A is generally confirmed when a child has a compatible clinical picture and pathogenic or likely pathogenic variants in both copies of the DNAJC6 gene. Genetic panels or exome sequencing are central; DaTscans and spinal taps are not routinely required.
Confirming a diagnosis of PARK19A (also known as DNAJC6-related parkinsonism) is a multi-step process that relies on genetic testing. Because the symptoms can overlap with other rare movement disorders or childhood-onset conditions, doctors use specific tests to rule out other possibilities and find the exact genetic cause [1][2].
The Gold Standard: Genetic Testing
A molecular diagnosis generally requires a compatible clinical picture plus biallelic pathogenic or likely pathogenic DNAJC6 variants. Because PARK19A is autosomal recessive, a child must have a mutation in both copies of the gene [3].
Doctors typically use one of two main genetic testing methods:
- Targeted Gene Panels: A “juvenile parkinsonism” or “early-onset movement disorder” panel tests a pre-selected group of genes known to cause similar symptoms [2].
- Whole Exome Sequencing (WES): If a panel doesn’t find the answer, WES looks at all the protein-coding regions of a child’s DNA. Exome or genome testing may also be used first-line in a child with developmental or multisystem disease [4][2].
Supporting Evidence: Imaging and CSF
While genetic testing provides the “name” of the condition, other tests have been used in research or to rule out other diseases [1].
- DaTscan (SPECT Imaging): In a small number of children with the severe juvenile form of PARK19A, these scans showed reduced or absent tracer uptake in the basal ganglia. However, DaTscans are not required for a molecular diagnosis [1].
- Cerebrospinal Fluid (CSF) Analysis: A lumbar puncture is not a routine confirmation test. In small studies:
Your Genetic Laboratory Report Checklist
When you receive the genetic laboratory report, it should contain several key pieces of information to confirm a diagnosis of PARK19A [6][3]:
- [ ] Gene Name: Must clearly list the DNAJC6 gene.
- [ ] Genotype Status: Must state the mutations affect both copies. This may be described as homozygous or compound heterozygous [6].
- [ ] Variant Classification: The mutations should be labeled as Pathogenic or Likely Pathogenic. A “Variant of Uncertain Significance” (VUS) cannot be used by itself to establish or rule out the diagnosis.
- [ ] Phase/Inheritance: Parental testing is helpful to confirm the mutations are “in trans,” meaning one was inherited from each parent, especially when there are two different variants [2].
- [ ] Mutation Detail: The report will use a code (e.g., c.1480del) to describe exactly where the gene is changed [6].
If the initial genetic test is negative but the doctor still strongly suspects PARK19A, they may order Deletion/Duplication Analysis to look for hidden changes that standard tests can miss [7][4].
Common questions in this guide
What confirms a diagnosis of PARK19A?
What does a biallelic DNAJC6 result mean?
Can a variant of uncertain significance diagnose PARK19A?
Are a DaTscan or spinal tap required to diagnose PARK19A?
What happens if the first genetic test is negative?
Why might parents have genetic testing after a child receives two DNAJC6 variants?
Get notified when new evidence is published on Juvenile onset Parkinson disease 19A.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (7)
- 1
DNAJC6 Mutations Disrupt Dopamine Homeostasis in Juvenile Parkinsonism-Dystonia.
Ng J, Cortès-Saladelafont E, Abela L, et al.
Movement disorders : official journal of the Movement Disorder Society 2020; (35(8)):1357-1368 doi:10.1002/mds.28063.
PMID: 32472658 - 2
Diagnosis of Primary Ciliary Dyskinesia by a Targeted Next-Generation Sequencing Panel: Molecular and Clinical Findings in Italian Patients.
Boaretto F, Snijders D, Salvoro C, et al.
The Journal of molecular diagnostics : JMD 2016; (18(6)):912-922 doi:10.1016/j.jmoldx.2016.07.002.
PMID: 27637300 - 3
DNAJC6 Mutations Associated With Early-Onset Parkinson's Disease.
Olgiati S, Quadri M, Fang M, et al.
Annals of neurology 2016; (79(2)):244-56 doi:10.1002/ana.24553.
PMID: 26528954 - 4
Whole-Exome Sequencing and Targeted Copy Number Analysis in Primary Ciliary Dyskinesia.
Marshall CR, Scherer SW, Zariwala MA, et al.
G3 (Bethesda, Md.) 2015; (5(8)):1775-81 doi:10.1534/g3.115.019851.
PMID: 26139845 - 5
Relationship of Genotype, Phenotype, and Treatment in Dopa-Responsive Dystonia: MDSGene Review.
Weissbach A, Pauly MG, Herzog R, et al.
Movement disorders : official journal of the Movement Disorder Society 2022; (37(2)):237-252 doi:10.1002/mds.28874.
PMID: 34908184 - 6
Childhood-onset parkinsonism, dystonia and severe muscle wasting in a Sudanese girl caused by a novel homozygous DnaJ heat shock protein family (heat shock protein 40) member C6 frameshift variant, with an incidental pathogenic breast cancer 1 gene secondary finding: a case report.
Ahmed KAHM, Ahmed RKY
Journal of medical case reports 2026; (20(1)).
PMID: 42897672 - 7
Hypotrichosis with juvenile macular dystrophy: Combination of whole-genome sequencing and genome-wide homozygosity mapping identifies a large deletion in CDH3 initially undetected by whole-exome sequencing-A lesson from next-generation sequencing.
Saeidian AH, Vahidnezhad H, Youssefian L, et al.
Molecular genetics & genomic medicine 2019; (7(11)):e975 doi:10.1002/mgg3.975.
PMID: 31560841
This page is for informational purposes only and does not constitute medical advice. A neurologist or genetics professional should interpret your child's genetic report and guide decisions about additional testing.